Catalog # 10-3306

Mocetinostat

CAS# 726169-73-9

N-(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide

MGCD0103

Lot # X107856



Class I, isoform-selective HDAC inhibitor, IC_{50}s=0.15, 0.29, 1.66 and 0.59 μM for HDAC1, 2, 3 and 11 respectively.[1] Induces hyperacetylation of histones, induces expression of the tumor suppressor p21WAF1 and inhibits proliferation of human cancer cells.[2] Displays antifibrotic effects in ischemic heart failure.[3] Attenuates the development of hypersensitivity in models of neuropathic pain.[4] Active *in vivo.*[5]

1) Zhou *et al*. (2008), *Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ulpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor*; J. Med. Chem., **51** 4072
2) Raeppel *et al*. (2009), *SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4((4-(pyridine-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103)*; Bioorg. Med. Chem. Lett., **19** 644
3) Nural-Guvener *et al*. (2015), *Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat is Associated with IL-6/Stat3 Signaling in Ischemic Heart Failure;* Int. J. Mol. Sci., **16** 11482
4) Denk *et al*. (2013), *HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain*; Pain, **154** 1668
5) Bonfils *et al*. (2008), *Evaluation of the pharmacodynamics effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay*; Clin. Cancer Res., **14** 3441

PHYSICAL DATA

Molecular Weight:	396.44
Molecular Formula:	$C_{23}H_{20}N_6O$
Purity:	98% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (up to 25 mg/ml)
Physical Description:	Off-white solid
Storage and Stability:	Store as supplied at -20°C for up to 2 years from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 2 months.

Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462

www.focusbiomolecules.com